# Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

> **NCT05572658** · — · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 10994 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05572658
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-15
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 10994 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572658, "Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05572658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*